Schizophrenia : Genes, environment and neurodevelopment;Gènes, environnement et neurodéveloppement : Le cas de la schizophrénie

Revue Medicale Suisse

Volumn 9, Issue 398, 2013, Pages 1672-1677

  Do, K Q ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

ARTICLE; ENVIRONMENTAL FACTOR; ENVIRONMENTAL IMPACT; GENETIC PREDISPOSITION; HEREDITY; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL LESION; OXIDATIVE STRESS; PHENOTYPE; RISK FACTOR; SCHIZOPHRENIA;

BRAIN; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84884867830     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Brown AS, McGrath JJ. The prevention of schizophrenia. Schizophr Bull 2011;37:257-61.
2. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : A multiple-treatments meta-analysis. Lancet 2013 ; epub ahead of print.
3. Bonsack C, Morandi S, Favrod J, Conus P. Stigma of «madness» from fate to recovery. Rev Med Suisse 2013;9:588-92.
4. Insel TR. Rethinking schizophrenia. Nature 2010; 468:187-93.
5. Doherty JL, O'Donovan MC, Owen MJ. Recent genomic advances in schizophrenia. Clin Genet 2012;81: 103-9.
6. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011;93:23-58.
7. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry 2011;19:109-24.
8. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia : From basic research to clinical practice. Curr Opin Psychiatry 2012;25:96-102.
9. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
10. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009;19:220-30.
11. Gysin R, et al. Impaired glutathione synthesis in schizophrenia : Convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007;104:6621-6.
12. Rodriguez-Santiago B, et al. Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. Mol Psychiatry 2010;15:1023-33.
13. Tosic M, et al. Schizophrenia and oxidative stress : Glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006;79:586-92.
14. Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-life insults impair parvalbumin interneurons via oxidative stress : Reversal by N-acetylcysteine. Biol Psychiatry 2013;73:574-82.
15. Steullet P, et al. Redox dysregulation affects the ventral but not dorsal hippocampus : Impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010;30:2547-58.
16. Cabungcal JH, et al. Perineuronal nets protect fastspiking interneurons against oxidative stress. Proc Natl Acad Sci USA 2013;110:9130-5.
17. Kulak A, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder : Insights from animal models. Antioxid Redox Signal 2013; 18:1428-43.
18. Duarte JM, et al. N-Acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biol Psychiatry 2012;71:1006-14.
19. Berk M, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64: 361-8.
20. Lavoie S, et al. Glutathione precursor, N-acetylcysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-99.
21. Baumann PS, et al. Treatment and early intervention in psychosis program (TIPP-Lausanne) : Implementation of an early intervention programme for psychosis in Switzerland. Early Interv Psychiatry 2013;7:322-8.
22. Amminger GP, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders : A randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54.